Latest Meridian Interstate Bancorp (EBSB) Headline
Post# of 27
Posted On: 03/12/2014 8:29:12 PM
Latest Meridian Interstate Bancorp (EBSB) Headlines
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:46AM CDT
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)?
Meridian Interstate Bancorp Has Returned 17.2% Since SmarTrend Recommendation (EBSB)
Comtex SmarTrend(R) - Fri Mar 07, 9:25AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.68. In approximately 2 month, Meridian Interstate Bancorp has returned 17.21% as of today's recent price of $27.75.
Meridian Interstate Bancorp, Inc. Announces Adoption of Plan of Conversion for Second-Step Stock Offering
GlobeNewswire - Wed Mar 05, 4:45PM CST
Meridian Interstate Bancorp, Inc. (the "Company") (Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank"), announced today that its Board of Directors, together with the Board of Trustees of Meridian Financial Services, Incorporated (the "MHC") and the Board of Directors of the Bank, have adopted a Plan of Conversion pursuant to which the Company will reorganize into a new stock holding company and will conduct a second-step stock offering of new shares of common stock.
Weakness Seen in Pulaski Financial (PULB) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:58AM CST
Pulaski Financial has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Kearny Financial Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 5:40PM CST
On Feb 12, Zacks Investment Research upgraded Kearny Financial Corp to a Zacks Rank #1 (Strong Buy).
Riverview Bancorp Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 2:26PM CST
Shares of Riverview Bancorp Inc. crafted a new 52-week high, touching $3.30 at the closing of the trading session on Feb 7
Meridian Interstate Bancorp, Inc. Reports Net Income for the Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Tue Jan 28, 3:15PM CST
Meridian Interstate Bancorp, Inc. (the "Company" or "Meridian") (Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank"), which also operates under the name Mt. Washington Bank, a Division of East Boston Savings Bank ("Mt. Washington"), announced net income of $4.0 million, or $0.18 per diluted share, for the quarter ended December 31, 2013, up from $2.1 million, or $0.10 per diluted share, for the quarter ended December 31, 2012. For the year ended December 31, 2013, net income was $15.4 million, or $0.70 per diluted share, up from $12.4 million, or $0.57 per diluted share, for the year ended December 31, 2012. The Company's return on average assets was 0.60% for the quarter ended December 31, 2013, up from 0.38% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average assets was 0.62%, up from 0.59% for the year ended December 31, 2012. The Company's return on average equity was 6.49% for the quarter ended December 31, 2013, up from 3.59% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average equity was 6.39%, up from 5.42% for the year ended December 31, 2012.
2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/x9nmsl/opportunityanalyze) has announced the addition of the "2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017" report to their offering. Cystic Fibrosis is caused by a genetic mutation which leads to the production of thickened sticky secretions in organs with epithelial cell linings, including the respiratory tract. Over time, lung infections lead to airway destruction, respiratory failure and death. The first-in-class CFTR modulator Kalydeco, a CFTR potentiator works to restore the function of the mutated CFTR protein in patients with the G551D gating mutation of CF, allowing an improved flow of salt and fluids on the surface of the lungs. Only around 4% of CF patients in the US have the G551D gating mutation, and more studies are needed to help determine whether people with other CF gating mutations might also be eligible for Kalydeco. Still, the drug's approval has paved the way for a new class of therapies, which offer a personalized treatment approach to patients and could be highly profitable for its developers. Vertex is now developing a combination therapy of potential first-in-class CFTR modulator lumacaftor (VX-809) with Kalydeco (VX-770) for the treatment of CF patients who are homozygous for the F508del mutation in the CFTR gene. The CFTR corrector, lumacaftor increases trafficking of the defective CFTR protein to the cell membrane, where it can exert its functions. The combination therapy is currently in Phase III stage of development, and is expected to gain approval in 2014. It is estimated that around half of all CF patients are homozygous to the F508del mutation, and Vertex has also announced plans to explore the lumacaftor/Kalydeco combination therapy in patients that are heterozygous to the F508del mutation. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Oppportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/x9...ityanalyze
Moody's May Downgrade First Niagara Ratings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 2:55PM CST
Moody's Investors Service - the credit rating arm of Moody's Corp. has placed the ratings of First Niagara Financial Group Inc. and its affiliates on review for a possible downgrade.
Zacks #1 Rank Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Wednesday
Zacks #1 Rank Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday
Banner Corp Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 19, 12:56PM CST
Shares of Banner Corporation crafted a new 52-week high, touching $39.95 in the first half of the trading session on Nov 18.
Uptrend Call Working As Meridian Interstate Bancorp Stock Rises 32.4% (EBSB)
Comtex SmarTrend(R) - Tue Nov 19, 9:15AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 25th, 2013 at $17.37. In approximately 10 months, Meridian Interstate Bancorp has returned 32.41% as of today's recent price of $23.00.
NYCB Reaches 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 14, 12:20PM CST
Shares of New York Community Bancorp Inc. hit a new 52-week high, touching $16.51 at the close of trading session on Nov 13.
Meridian Interstate Bancorp Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 13, 2:20PM CST
On Nov 12, Zacks Investment Research upgraded Meridian Interstate Bancorp, Inc. (EBSB) to a Zacks Rank #1 (Strong Buy).
Sterling Financial Reaches 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 13, 1:10PM CST
Shares of Sterling Financial Corporation hit a new 52-week high, touching $30.76 in the first half of the trading session on Nov 12.
Meridian Interstate Bancorp Up 33.9% Since SmarTrend Uptrend Call (EBSB)
Comtex SmarTrend(R) - Mon Nov 11, 4:54PM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 25th, 2013 at $17.37. In approximately 10 months, Meridian Interstate Bancorp has returned 33.94% as of today's recent price of $23.26.
Northfield Bancorp Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 06, 2:23PM CST
On Nov 5, Zacks Investment Research upgraded Northfield Bancorp to a Zacks Rank #1 (Strong Buy).
Meridian Interstate Bancorp Has Returned 35.3% Since SmarTrend Recommendation (EBSB)
Comtex SmarTrend(R) - Mon Nov 04, 11:05AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 25th, 2013 at $17.37. In approximately 9 months, Meridian Interstate Bancorp has returned 35.35% as of today's recent price of $23.51.
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:46AM CDT
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)?
Meridian Interstate Bancorp Has Returned 17.2% Since SmarTrend Recommendation (EBSB)
Comtex SmarTrend(R) - Fri Mar 07, 9:25AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.68. In approximately 2 month, Meridian Interstate Bancorp has returned 17.21% as of today's recent price of $27.75.
Meridian Interstate Bancorp, Inc. Announces Adoption of Plan of Conversion for Second-Step Stock Offering
GlobeNewswire - Wed Mar 05, 4:45PM CST
Meridian Interstate Bancorp, Inc. (the "Company") (Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank"), announced today that its Board of Directors, together with the Board of Trustees of Meridian Financial Services, Incorporated (the "MHC") and the Board of Directors of the Bank, have adopted a Plan of Conversion pursuant to which the Company will reorganize into a new stock holding company and will conduct a second-step stock offering of new shares of common stock.
Weakness Seen in Pulaski Financial (PULB) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:58AM CST
Pulaski Financial has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Kearny Financial Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 5:40PM CST
On Feb 12, Zacks Investment Research upgraded Kearny Financial Corp to a Zacks Rank #1 (Strong Buy).
Riverview Bancorp Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 2:26PM CST
Shares of Riverview Bancorp Inc. crafted a new 52-week high, touching $3.30 at the closing of the trading session on Feb 7
Meridian Interstate Bancorp, Inc. Reports Net Income for the Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Tue Jan 28, 3:15PM CST
Meridian Interstate Bancorp, Inc. (the "Company" or "Meridian") (Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank"), which also operates under the name Mt. Washington Bank, a Division of East Boston Savings Bank ("Mt. Washington"), announced net income of $4.0 million, or $0.18 per diluted share, for the quarter ended December 31, 2013, up from $2.1 million, or $0.10 per diluted share, for the quarter ended December 31, 2012. For the year ended December 31, 2013, net income was $15.4 million, or $0.70 per diluted share, up from $12.4 million, or $0.57 per diluted share, for the year ended December 31, 2012. The Company's return on average assets was 0.60% for the quarter ended December 31, 2013, up from 0.38% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average assets was 0.62%, up from 0.59% for the year ended December 31, 2012. The Company's return on average equity was 6.49% for the quarter ended December 31, 2013, up from 3.59% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average equity was 6.39%, up from 5.42% for the year ended December 31, 2012.
2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/x9nmsl/opportunityanalyze) has announced the addition of the "2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017" report to their offering. Cystic Fibrosis is caused by a genetic mutation which leads to the production of thickened sticky secretions in organs with epithelial cell linings, including the respiratory tract. Over time, lung infections lead to airway destruction, respiratory failure and death. The first-in-class CFTR modulator Kalydeco, a CFTR potentiator works to restore the function of the mutated CFTR protein in patients with the G551D gating mutation of CF, allowing an improved flow of salt and fluids on the surface of the lungs. Only around 4% of CF patients in the US have the G551D gating mutation, and more studies are needed to help determine whether people with other CF gating mutations might also be eligible for Kalydeco. Still, the drug's approval has paved the way for a new class of therapies, which offer a personalized treatment approach to patients and could be highly profitable for its developers. Vertex is now developing a combination therapy of potential first-in-class CFTR modulator lumacaftor (VX-809) with Kalydeco (VX-770) for the treatment of CF patients who are homozygous for the F508del mutation in the CFTR gene. The CFTR corrector, lumacaftor increases trafficking of the defective CFTR protein to the cell membrane, where it can exert its functions. The combination therapy is currently in Phase III stage of development, and is expected to gain approval in 2014. It is estimated that around half of all CF patients are homozygous to the F508del mutation, and Vertex has also announced plans to explore the lumacaftor/Kalydeco combination therapy in patients that are heterozygous to the F508del mutation. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Oppportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/x9...ityanalyze
Moody's May Downgrade First Niagara Ratings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 2:55PM CST
Moody's Investors Service - the credit rating arm of Moody's Corp. has placed the ratings of First Niagara Financial Group Inc. and its affiliates on review for a possible downgrade.
Zacks #1 Rank Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Wednesday
Zacks #1 Rank Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday
Banner Corp Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 19, 12:56PM CST
Shares of Banner Corporation crafted a new 52-week high, touching $39.95 in the first half of the trading session on Nov 18.
Uptrend Call Working As Meridian Interstate Bancorp Stock Rises 32.4% (EBSB)
Comtex SmarTrend(R) - Tue Nov 19, 9:15AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 25th, 2013 at $17.37. In approximately 10 months, Meridian Interstate Bancorp has returned 32.41% as of today's recent price of $23.00.
NYCB Reaches 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 14, 12:20PM CST
Shares of New York Community Bancorp Inc. hit a new 52-week high, touching $16.51 at the close of trading session on Nov 13.
Meridian Interstate Bancorp Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 13, 2:20PM CST
On Nov 12, Zacks Investment Research upgraded Meridian Interstate Bancorp, Inc. (EBSB) to a Zacks Rank #1 (Strong Buy).
Sterling Financial Reaches 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 13, 1:10PM CST
Shares of Sterling Financial Corporation hit a new 52-week high, touching $30.76 in the first half of the trading session on Nov 12.
Meridian Interstate Bancorp Up 33.9% Since SmarTrend Uptrend Call (EBSB)
Comtex SmarTrend(R) - Mon Nov 11, 4:54PM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 25th, 2013 at $17.37. In approximately 10 months, Meridian Interstate Bancorp has returned 33.94% as of today's recent price of $23.26.
Northfield Bancorp Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 06, 2:23PM CST
On Nov 5, Zacks Investment Research upgraded Northfield Bancorp to a Zacks Rank #1 (Strong Buy).
Meridian Interstate Bancorp Has Returned 35.3% Since SmarTrend Recommendation (EBSB)
Comtex SmarTrend(R) - Mon Nov 04, 11:05AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 25th, 2013 at $17.37. In approximately 9 months, Meridian Interstate Bancorp has returned 35.35% as of today's recent price of $23.51.
(0)
(0)Meridian Interstate Bancorp (EBSB) Stock Research Links
Scroll down for more posts ▼